Month: March 2022

FY 2021 Net Revenues Up 22.9% to $125.4 million; Net Income of $3.3 million BOCA RATON, Fla., March 30, 2022 (GLOBE NEWSWIRE) — FlexShopper, Inc. (Nasdaq:FPAY) (“FlexShopper”), a leading national online lease-to-own (“LTO”) retailer and LTO payment solution provider, today announced its financial results for the quarter and fiscal year ended December 31, 2021, highlighted by increase in revenue and net income. Results for Quarter Ended December 31, 2021 vs. Quarter Ended December 31, 2020:Total net revenues and fees increased 10.5% to $31.1 million from $28.1 millionOriginated 51,071 gross leases, down 28.4% from 71,350; average origination value increased by 13.6% to $527Net income of $633 thousand compared with net loss of $(419) thousandNet income attributable to common stockholders of $23 thousand, or $0.00 per diluted...

– Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen – – Company anticipates topline, interim data for RSV lead program IVX-121 in 2Q 2022 – – Announced emerging program in flu, as part of strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults – – Reported topline Phase 1/2 results for IVX-411 Against SARS-CoV-2 – SEATTLE, March 30, 2022 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision...

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. “We continue to devote all of our development effort to bringing expanded therapeutic options to people living with ulcerative colitis (UC),” said Preston Klassen, M.D., MHS, CEO, Metacrine. “We have generated preclinical data that supports moving our MET642 program into clinical testing in UC during the next few months. In addition, by reducing our organizational footprint as part of our recently implemented restructuring plan, we expect that our cash runway will fund operations through 2023 as we evaluate a range of ways to generate value from our discovery programs, product...

Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021 New Twirla Connected TV Commercial Expected to launch in April 2022 and Contribute to Further Demand Growth Company Advances Business Plan Designed to Target Resources on Building Momentum for Twirla Management to Host Conference Call Today, Wednesday, March 30, 2022 at 4:30 p.m. ET PRINCETON, N.J., March 30, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and twelve months ended December 31, 2021 and provided a corporate update. “2021 was our first full year of commercializing Twirla, and I am proud of what our team was able to accomplish. We believe we created a solid foundation for...

Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million, respectively Full national launch of UPNEEQ into medical aesthetics market in February 2022 First quarter 2022 UPNEEQ product sales expected to be in the range of $5.5 to 6.0 million Fourth quarter 2022 UPNEEQ revenue guidance of $20.0 to 25.0 million reaffirmed Received $5 million from contingent milestones related to divestiture of the legacy business with additional $15.5 million expected from amendment of UPNEEQ License Agreement BRIDGEWATER, N.J., March 30, 2022 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced financial results and business highlights...

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — Kubient, Inc. (NasdaqCM: KBNT, KBNTW) (“Kubient” or the “Company”), a cloud-based software platform for digital advertising, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 and Recent Operational HighlightsAcqui-hired MediaCrossing Inc., a premier digital advertising agency dedicated to bringing advertising tools, technologies and expertise to brands, to operate within Kubient’s Managed Services division. Appointed Mitchell Berg as the Company’s Chief Technology Officer (“CTO”), who brings more than 20 years of technology, engineering, and executive management experience to the Kubient management team. Partnered with Verve Group, an omnichannel ad platform, to increase transparency and reduce fraud in the advertising...

BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO® (nivolumab) progressing well Preclinical data on multiple pipeline programs will be presented at AACR 2022, including BDC-2034, BDC-3042, and a PD-L1 ISAC Cash balance of $272 million expected to fund key milestones and operations into 2024REDWOOD CITY, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an...

— Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases — Ended the year with nearly $89M in cash and cash equivalents UNIONDALE, N.Y., March 30, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today reported its financial results for full year 2021. “In 2022, we are focused on advancing Angion’s lead clinical development candidate ANG-3070 for the treatment of patients with primary proteinuric kidney diseases and continuing the enrollment of JUNIPER, our Phase 2 dose-finding study in focal segmental glomerular sclerosis and IgA nephropathy patients,” said Dr. Jay R. Venkatesan,...

2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. “Clarus delivered solid growth in net revenue as a new public company driven by continued demand for JATENZO,” said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. “We also...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory HighlightsAnnounced strategic focus on developing and commercializing therapeutics targeting rare central nervous system (CNS) and neurodegenerative conditions; Advancing development of KP1077, a serdexmethylphenidate (SDX) based product candidate for idiopathic hypersomnia (IH), as KemPharm’s lead candidate:Pre-Investigational New Drug (IND) process with the U.S. Food and Drug Administration (FDA) successfully completed in February 2022; IND filing expected as early as the second quarter of 2022; Phase 2 trial initiation expected in the second half of 2022; and Reported data from the Phase 1 clinical trial exploring the safety and pharmacokinetics (PK) of “higher-dose” SDX which validates selection...